Evidence map›Paper›PMID 37125917›Full record

ArticleMicrobiology spectrum2023

The

Ishani Wickramage, Zhong Peng, Soumyadeep Chakraborty, Céline Harmanus, Ed J Kuijper, Sally Alrabaa, Wiep Klaas Smits, Xingmin Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ishani WickramageDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.ORCID 0000-0002-0397-3428
Zhong PengDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Soumyadeep ChakrabortyDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Céline HarmanusDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Ed J KuijperDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-5726-2405
Sally AlrabaaDepartment of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Wiep Klaas SmitsDepartment of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-7409-2847
Xingmin SunDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.ORCID 0000-0002-8900-9161
University of South Florida · USLeiden University Medical Center · NL

Funding

Multivalent vaccines against Clostridium difficile infectionR01AI132711 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI Xingmin Sun, Shifeng Wang · 2017 to 2026
$3.3M
Novel polymer biomaterials combating C. difficile infectionR01AI149852 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG, SUN, XINGMIN · 2019 to 2023
$1.9M
Effect of bile salt hydrolase inhibitors on Clostridium difficile infectionR21AI159745 · NIAID · UNIVERSITY OF TENNESSEE KNOXVILLE · PI LIN, JUN, SUN, XINGMIN · 2021 to 2022
$416k
NIAID NIH HHS R01 AI132711NIAID NIH HHS R01 AI149852NIAID NIH HHS R21 AI159745
6 · The paper itself

Abstract

Clostridioides difficile, the primary cause of nosocomial antibiotic-associated diarrhea, has a complex relationship with antibiotics. While the use of broad-spectrum antibiotics disrupts the gut microbiota and increases the risk of C. difficile infection (CDI), antibiotics are also the primary treatment for CDI. However, only a few antibiotics, including vancomycin, fidaxomicin, and rifaximin, are effective against CDI, and resistance to these antibiotics has emerged recently. In this study, we report the identification of two RT027 C. difficile clinical isolates (TGH35 and TGH64) obtained from symptomatic CDI-diagnosed patients in Tampa, Florida in 2016. These two strains showed an elevated minimum inhibitory concentration (MIC) of vancomycin (MIC = 4 μg/mL, compared to the EUCAST breakpoint of 2 μg/mL) and contained a

Indexed as

Clostridioides difficileClostridium InfectionsAnti-Bacterial AgentsCadmiumClostridioidesDiarrheaFloridaHumansMicrobial Sensitivity TestsRifaximinVancomycinAnti-Bacterial AgentsCadmiumRifaximinVancomycinantibiotic resistanceClostridioides difficilenovel resistance-determining mechanismsreduced susceptibility to vancomycinsingle base pair mutationvancomycinvanGCd operonvan operonvanRCd

Identifiers

PMID37125917
PMCPMC10269549
OpenAlexW4367599348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.